claim: early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increase mortality
evidence_1: in the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of covid-19 patients soon after hospitalization with high titer anti-spike protein rbd igg present in convalescent plasma significantly reduces mortality.", "transfusion of convalescent plasma collected from donors who have recovered from covid-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the u.s. food and drug administration (fda).", "with respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing covid-19 patients with high titer convalescent plasma.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "we recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of covid-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (rbd) igg significantly decreases mortality.")